Mucoadhesive fenretinide-releasing system (FMS)

Phase 1Small molecule

Mucoadhesive fenretinide-releasing system (FMS) is one of 3 small molecule programs targeting Oral leukoplakia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral LeukoplakiaActive, not recruiting

Oral LeukoplakiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Oral Leukoplakia

#DrugCompanyPhaseTrials

Bayer Aspirin

Glucophage

1 3

Mucoadhesive fenretinide-releasing system (FMS)

OOhio State University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral leukoplakia1 trial

Safety and Chemopreventive Efficacy of Fenretinide Mucoadhesive System in Subjects With Premalignant Oral Intraepithelial Neoplasia (OIN) Lesions: In Conjunction With Pharmacokinetic Assessment in Healthy Subjects.

Active, not recruiting·OOhio State University·Phase 1·NCT07149220·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mucoadhesive fenretinide-releasing system (FMS). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mucoadhesive fenretinide-releasing system (FMS) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mucoadhesive fenretinide-releasing system (FMS). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ohio State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OOhio State University

Mucoadhesive fenretinide-releasing system (FMS)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral leukoplakia1 trial

References

Drug Info

Quick Facts

Related News